A study to compare the efficacy of gabapentin plus amitryptiline with amitryptiline alone for management of chemotherapy induced peripheral neuropathy.

A comparative study to see the efficacy of combination of gabapentin and amitryptiline versus amitryptiline alone for the management of chemotherapy induced peripheral neuropathy (CIPN).

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/07/009109

Enrollment

Registered

2017-07-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G620- Drug-induced polyneuropathy

Interventions

Intervention1: Combination ofGabapentin plus Amitryptiline: gabapaentin 600 mg/d and amitryptiline10mg/d in the 1st week and gabapentin 900mg/d with amitryptiline 10mg/d from 2nd week for total 3 mont

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with cancer having neuropathic pain. 2. Patient on WHO ladder therapy for control of cancer related pain.

Exclusion criteria

Exclusion criteria: 1. Patients with unstable cardiovascular, respiratory, hepatic or hematological disease or psychological disorder. 2. Patient having diabetes, HIV, Guillain-BarrÃ© syndrome, CIDP, radiculopathy. 3. Alchoholic,drug abuse patient.

Design outcomes

Primary

Measure	Time frame
Intensity of pain in Numeric Rating Scale (NRS)Timepoint: Intensity of pain in Numeric Rating Scale (NRS)	—

Secondary

Measure	Time frame
NilTimepoint: NA	—

Countries

India

Contacts

Public ContactDr Subrata Goswami

ESI Institute of Pain Management

drsgoswami@gmail.com9830430430

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026